Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions

Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions

For differentiated thyroid cancer (DTC), systemic therapy with radioactive iodine (RAI) is utilized for radiosensitive disease, while for radioiodine refractory (RAIR) disease, current standard of care is treatment with multikinase tyrosine kinase inhibitors (TKI). For BRAF-mutant DTC or anaplastic...

Full description

Bibliographic Details
Main Authors:	Ashleigh Porter, Deborah J. Wong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Oncology
Subjects:	thyroid cancer tyrosine kinase inhibitor BRAF mutation V600 mechanisms of resistance to therapy anaplastic thyroid cancer medullary thyroid cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.592202/full

Similar Items

A case report of simultaneous medullary and papillary carcinoma of thyroid
by: Ziaolhagh Reza, et al.
Published: (2021-04-01)

The Use of Tyrosine Kinase Inhibitors in Advanced Medullary Thyroid Cancer-Single Center Experience
by: Senar Ebinç, et al.
Published: (2021-03-01)

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
by: Dagmara Rusinek, et al.
Published: (2017-08-01)

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
by: Loredana Lorusso, et al.
Published: (2021-03-01)

Disseminated medullary thyroid carcinoma. Optimal approach to treatment
by: I. S. Romanov, et al.
Published: (2019-01-01)

Breast metastasis from medullary thyroid carcinoma in a male patient: case report and review of the literature
by: Stylianos Mandanas, et al.
Published: (2015-05-01)

Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report
by: Takahiro Fukuhara, et al.
Published: (2017-02-01)

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
by: Soo Young Kim, et al.
Published: (2020-09-01)

2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer
by: V V Voskoboynikov, et al.
Published: (2013-06-01)

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer
by: Chiara Romano, et al.
Published: (2021-07-01)

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
by: Elena Tirrò, et al.
Published: (2019-09-01)

Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration
by: Silvia Martina Ferrari, et al.
Published: (2018-12-01)

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
by: Fabiana Crispo, et al.
Published: (2019-09-01)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
by: Dagmara Rusinek, et al.
Published: (2018-09-01)

Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)
by: I. S. Romanov, et al.
Published: (2020-07-01)

Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decades at a Single Oncology Referral Centre and Novel Therapeutic Options
by: Joana Simões-Pereira, et al.
Published: (2019-08-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
by: А. М. Mudunov, et al.
Published: (2019-10-01)

Apatinib-treated advanced medullary thyroid carcinoma: a case report
by: Chen K, et al.
Published: (2018-01-01)

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience
by: Matea Pešorda, et al.
Published: (2020-01-01)

Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
by: Mohamed Aashiq, et al.
Published: (2019-09-01)

Recent Updates on the Management of Medullary Thyroid Carcinoma
by: Bo Hyun Kim, et al.
Published: (2016-09-01)

Anaplastic thyroid cancer. Is there a light at the end of the tunnel?
by: A. L. Pylev, et al.
Published: (2020-04-01)

Targeted Therapy for Medullary Thyroid Cancer: A Review
by: S. R. Priya, et al.
Published: (2017-10-01)

Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series
by: Danielle Pessôa-Pereira, et al.
Published: (2019-03-01)

Prevalence of BRAF Mutation in Papillary Thyroid Cancer
by: Shatha Dmour, et al.
Published: (2016-12-01)

Update on Targeted Therapy in Medullary Thyroid Cancer
by: Christian Okafor, et al.
Published: (2021-08-01)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
by: Costa R, et al.
Published: (2016-02-01)

Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma
by: C Gopalakrishnan Nair, et al.
Published: (2017-01-01)

Higher Integrin Alpha 3 Beta1 Expression in Papillary Thyroid Cancer Is Associated with Worst Outcome
by: Lorenza Mautone, et al.
Published: (2021-06-01)

Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics
by: Martina Tavarelli, et al.
Published: (2017-10-01)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
by: Angelica Schmidt, et al.
Published: (2017-02-01)

Alcohol abuse as a risk factor for developing thyroid cancer
by: Kalezić Nevena, et al.
Published: (2021-01-01)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
by: Xuelong Jiao, et al.
Published: (2018-09-01)

Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study
by: Marialuisa Appetecchia, et al.
Published: (2019-10-01)

Anaplastic Thyroid Cancer: Experience of the Philippine General Hospital
by: Tom Edward Lo, et al.
Published: (2015-06-01)

Improvement of Overall Survival using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience
by: Lucia Brilli, et al.
Published: (2021-01-01)

FAMILIAL NON MEDULLARY THYROID CANCER (FNMTC) REPRESENTS AN INDEPENDENT RISK FACTOR FOR INCREASED CANCER AGGRESSIVENESS: A RETROSPECTIVE ANALYSIS OF 74 FAMILIES
by: Martina eTavarelli, et al.
Published: (2015-08-01)

Comparative investigation of antitumoral effectiveness of Rho-kinase inhibitor Y-27632, pravastatin and atorvastatin in anaplastic thyroid cancer cell culture
by: Erdinc Nayir, et al.
Published: (2017-07-01)

To screen or not to screen for medullary thyroid cancer? This is (yet) the question. An illustrative case.
by: Rosaria Ruggeri, et al.
Published: (2018-12-01)

Anaplastic Carcinoma Thyroid in a Young Child – an Extremely Rare Occurrence
by: Suresh Chandra Sharma, et al.
Published: (2019-01-01)

Cannot write session to /tmp/vufind_sessions/sess_o35j1vgvadksfuhvqbr873478d